Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib.

about

Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib.

Item

http://www.wikidata.org/entity/Q47138737

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib.

@en

Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib.

@nl

type

Item

label

Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib.

@en

Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib.

@nl

prefLabel

Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib.

@en

Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib.

@nl

P1476

Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib.

@en

P2093

Bin Zhao

http://www.w3.org/2001/XMLSchema#string

Hong Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1

Bias in meta-analysis detected by a simple, graphical test

Operating characteristics of a rank correlation test for publication bias

Measuring inconsistency in meta-analyses

CXCR4 over-expression and survival in cancer: a system review and meta-analysis

Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials.

Haematologic toxicities associated with the addition of bevacizumab in cancer patients.

P304

93813-93824

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.21217

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29212191

http://www.w3.org/2001/XMLSchema#string

P932

5706837

http://www.w3.org/2001/XMLSchema#string